Alessandra Gnani

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 512 citations · Full text

Medicine, Hematology, Oncology +15

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Haematologica · 2007 · 190 citations · Full text

Medicine, Oncology, Pharmacology +11

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Simona Soverini, Alessandra Gnani, Sabrina Colarossi et al. · Blood · 2009 · 174 citations · Full text

Medicine, Genetics, Oncology +16

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

Simona Soverini, Alessandro Vitale, Antonio Poerio et al. · Haematologica · 2010 · 93 citations · Full text

Medicine, Hematology, Oncology +17

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

Simona Soverini, Giovanni Martinelli, Sabrina Colarossi et al. · The Lancet Oncology · 2007 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +7